Fundz

Passage Bio

Philadelphia, United States · Biotechnology, Genetics, Healthcare

Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.

Key facts

Headquarters
Philadelphia, United States
Employees
83
Industries
Biotechnology, Genetics, Healthcare
Status
Public (PASG)
Website
passagebio.com
LinkedIn
Company page

Recent activity at Passage Bio

  • : Passage Bio to merge with Remix Therapeutics
  • : Passage Bio Terminates Lease Agreement with Hopewell Campus Owner LLC (date Fundz recorded it)
  • : SEC 8-K (5.02): On November 5, 2026, Passage Bio, Inc. conducted a Special Meeting of Stockholders where the stockholders approved the 2026 Equity Incentive Plan (the '2026 Plan'), which will replace the existing 2018 and 2020 Equity Incentive Plans and Remix's 2019 Plan, contingent on the completion of the First Merger with Remix Therapeutics, Inc. The 2026 Plan reserves a total of approximately 5,772,500 shares for issuance, with the potential for annual increases beginning January 1, 2027. The plan will also allow for the conversion of outstanding Remix stock options into Passage Bio shares at a predetermined exchange ratio. This transition is significant as it streamlines the stock incentive framework and may impact future compensation strategies for employees of the merged entity.
  • : SEC 8-K (1.01): On September 2, 2026, Passage Bio, Inc. entered into an Amended and Restated Merger Agreement with Peregrine Merger Sub, Inc., a wholly owned subsidiary of the Company, and Remix Therapeutics, Inc. This agreement involves a strategic merger designed to advance Passage Bio's capabilities in gene therapy, which is critical for both companies' future product development. The original merger agreement, dated June 24, 2026, lays the foundation for this amendment, enabling Passage Bio to enhance its operational structure and potentially improve market positioning. The merger is subject to specified conditions which if satisfied, could lead to a significant transformation in the combined entities. Details regarding financial terms and implications were not disclosed in this initial filing.
  • : SEC 8-K (5.02): On June 23, 2026, Passage Bio delivered a written notice to The Trustees of the University of Pennsylvania to terminate the Second Amended and Restated Research, Collaboration and License Agreement specifically regarding the licensed product 'PBFT02', which includes indications for frontotemporal dementia with granulin mutations. This termination is pursuant to Section 10.2 of the agreement and will take effect ninety days after Penn's receipt of the notice. Following the termination, Passage Bio will lose rights to develop or commercialize PBFT02 under this agreement, although the contract will continue to apply to all other licensed products. The strategic implications of this decision suggest a shift in focus away from PBFT02, which may affect the company's development pipeline and partnerships.
  • : SEC 8-K (1.02): On May 21, 2026, Passage Bio, Inc. terminated its research, collaboration, and license agreement with Gemma Biotherapeutics, Inc. The termination, effective as per the agreement's terms, affects ongoing research programs in Huntington's disease and paused research in Temporal Lobe Epilepsy. Additionally, on May 22, 2026, Passage Bio entered into a lease termination agreement with Commerce Square Partners, paying a $2.3 million fee to conclude a lease for approximately 37,000 square feet of office space set to expire in December 2031. This lease had commenced in February 2021, with prior sublease agreements established in 2023, indicating a strategic shift in their office space usage. These terminations illustrate the company's restructuring efforts amidst changing operational needs.
  • : SEC 8-K (2.05): On April 28, 2026, Passage Bio, Inc. announced a Restructuring Plan to reduce its workforce by approximately 75% as part of its strategic efforts to maximize shareholder value. This significant personnel reduction is expected to incur exit costs totaling approximately $3.3 million, primarily recorded in the second quarter of 2026. Impacted employees will receive severance benefits contingent upon signing severance agreements, which include a general release of claims against the company. The Restructuring Plan aims to substantially complete the workforce adjustments in the second and third quarters of 2026, thereby decreasing the company's operating expenses significantly.
  • : SEC 8-K (7.01): On April 20, 2026, Passage Bio, Inc. announced important updates regarding their PBFT02 program, which is in a Phase 1/2 clinical trial for the treatment of frontotemporal dementia caused by progranulin deficiency. The company provided interim data showing significant reductions in brain atrophy and stabilization of plasma neurofilament levels in treated patients, which suggests promising efficacy. Additionally, they completed a Type C meeting with the FDA to discuss the framework of a potential future registrational trial for PBFT02, indicating proactive regulatory engagement to progress their treatment options. These developments are crucial for the stakeholders as they may impact future clinical trial progress and product approval timelines.
  • : SEC 8-K (1.02):
  • : SEC 8-K (7.01): On March 3, 2026, Passage Bio, Inc. updated its corporate presentation, which has been attached as Exhibit 99.2 to the filing. This disclosure falls under Regulation FD, indicating the company's commitment to share significant information with all investors. The accompanying press release also issued on the same date outlines the company's financial results for the year ended December 31, 2025, signaling potential strategic insights into its recent performance. The company emphasizes that the information in this report is not intended to be filed under certain sections of the Exchange Act or Securities Act.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Passage Bio funding history

DateRoundAmount
Feb 2022Seed$4.0M
Sep 2019Venture$110.0M

Leadership

  • Justin Poley, Executive Director, Manufacturing Operations.
  • Thomas Woiwode, Director
  • Saqib Islam, Director
  • Tadataka Yamada, Executive Officer, Director, Promoter
  • Carl Gordon, Director
  • Patrick Heron, Director
  • Stephen Squinto, Executive Officer, Director
  • Will Chou, Chief Executive Officer

Verified email and direct lines for Passage Bio’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Passage Bio in the news

Companies similar to Passage Bio

About Passage Bio: questions and answers

What does Passage Bio do?

Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.

Where is Passage Bio headquartered?

Passage Bio is headquartered in Philadelphia, United States.

How many employees does Passage Bio have?

Passage Bio has about 83 employees.

Has Passage Bio raised funding?

Yes. Fundz has recorded 2 funding events for Passage Bio. The most recent, Seed of $4.0M, was in Feb 2022.

Who leads Passage Bio?

Will Chou is a Chief Executive Officer at Passage Bio.

What is the latest news on Passage Bio?

On Jun 24, 2026, Passage Bio to merge with Remix Therapeutics

Is Passage Bio a public company?

Yes. Passage Bio is publicly traded under the ticker PASG.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Passage Bio across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.